Global Mental Illness Drugs Market

Mental Illness Drugs Comprehensive Study by Type (Antipsychotics, Antidepressants, Antianxiety (anxiolytics), Anti-seizure medications), Application (Hospital, Clinic, Drugstore), Distribution Channel (Online, Offline), Type Disorders (Anxiety disorders, Depression, bipolar disorder, Eating disorders, Personality disorders, Post-traumatic stress disorder, Others), Dosage (Oral, Injectables) Players and Region - Global Market Outlook to 2028

Mental Illness Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Mental Illness Drugs Market?

A mental disorder can be explained as a psychological anomaly that is reflected in a patient’s behavior through disability, distress, or any conduct that is not considered normal mental development. The causes of mental disorders are very diverse and often unclear in most cases. However, some of the commonly addressed drug classes for the treatment of mental disorders are anxiolytics, antidepressants, and antipsychotics. Some of the common mental disorders affecting millions around the world are depression, schizophrenia, and intellectual disabilities, and disorders due to drug abuse.WHO’s reviewed fact sheet, as of 2016 over 350 million people worldwide are affected by depression, over 60 million people are diagnosed with bipolar disorder, and almost 21 million people around the world have schizophrenia and other psychoses. The incidence is rising and there is less likely for it to subside anytime soon. Governments around the world are thus focusing on developing effective treatment and drugs to eliminate the prevalence of mental disorders.

Highlights from Mental Illness Drugs Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledJohnson and Johnson (United States), Pfizer (United States), Eli Lilly and Company (United States), GlaxoSmithKline (United Kingdom), AstraZeneca(United States), Bristol-Myers Squibb (United States), Alkermes (Ireland) and Allergan (United States)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Mental Illness Drugs market throughout the forecasted period.

Johnson and Johnson (United States), Pfizer (United States), Eli Lilly and Company (United States), GlaxoSmithKline (United Kingdom), AstraZeneca(United States), Bristol-Myers Squibb (United States), Alkermes (Ireland) and Allergan (United States) are some of the key players profiled in the study.

Mental Illness Drugs Market Segmentation:
ScopeSub-Segments
Application / End UserHospital, Clinic and Drugstore
TypeAntipsychotics, Antidepressants, Antianxiety (anxiolytics) and Anti-seizure medications
Distribution ChannelOnline,Offline
Type DisordersAnxiety disorders,Depression, bipolar disorder,Eating disorders,Personality disorders,Post-traumatic stress disorder,Others
DosageOral,Injectables


On the basis of geography, the market of Mental Illness Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
The increase in the number of patients taking treatment and Rising demand for improved healthcare infrastructure are expected to drive the market.

Challenges:
Stringent regulations for drug patents

Restraints:
The adverse effect of the drugs

Opportunities:
The Growing burden of the disease and the increasing need to manage it effectively is driving the growth of the market studied.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Mental Illness Drugs sd Manufacturer, Government Regulatory and Research Organizations and End-Use Industry


“In December 2016, the 21st Century Cures Act was signed into law. The Cures Act addresses many critical issues including leadership and accountability for behavioral health disorders at the federal level, the importance of evidence-based programs and prevention of mental and substance use disorders, and the imperative to coordinate efforts across government.” and “The Mental Health Parity and Addiction Equity Act of 2008 requires insurance groups offering coverage for mental health or substance use disorders to make these benefits comparable to general medical coverage. Deductibles, copays, out-of-pocket maximums, treatment limitations, etc., for mental health or substance use disorders, must be no more restrictive than the same requirements or benefits offered for other medical care.”

Report Objectives / Segmentation Covered

By Type
  • Antipsychotics
  • Antidepressants
  • Antianxiety (anxiolytics)
  • Anti-seizure medications
By Application
  • Hospital
  • Clinic
  • Drugstore
By Distribution Channel
  • Online
  • Offline

By Type Disorders
  • Anxiety disorders
  • Depression, bipolar disorder
  • Eating disorders
  • Personality disorders
  • Post-traumatic stress disorder
  • Others

By Dosage
  • Oral
  • Injectables

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increase in the number of patients taking treatment
      • 3.2.2. Rising demand for improved healthcare infrastructure are expected to drive the market.
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulations for drug patents
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mental Illness Drugs, by Type, Application, Distribution Channel, Type Disorders, Dosage and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Mental Illness Drugs (Value)
      • 5.2.1. Global Mental Illness Drugs by: Type (Value)
        • 5.2.1.1. Antipsychotics
        • 5.2.1.2. Antidepressants
        • 5.2.1.3. Antianxiety (anxiolytics)
        • 5.2.1.4. Anti-seizure medications
      • 5.2.2. Global Mental Illness Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Drugstore
      • 5.2.3. Global Mental Illness Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Mental Illness Drugs by: Type Disorders (Value)
        • 5.2.4.1. Anxiety disorders
        • 5.2.4.2. Depression, bipolar disorder
        • 5.2.4.3. Eating disorders
        • 5.2.4.4. Personality disorders
        • 5.2.4.5. Post-traumatic stress disorder
        • 5.2.4.6. Others
      • 5.2.5. Global Mental Illness Drugs by: Dosage (Value)
        • 5.2.5.1. Oral
        • 5.2.5.2. Injectables
      • 5.2.6. Global Mental Illness Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Mental Illness Drugs (Volume)
      • 5.3.1. Global Mental Illness Drugs by: Type (Volume)
        • 5.3.1.1. Antipsychotics
        • 5.3.1.2. Antidepressants
        • 5.3.1.3. Antianxiety (anxiolytics)
        • 5.3.1.4. Anti-seizure medications
      • 5.3.2. Global Mental Illness Drugs by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Drugstore
      • 5.3.3. Global Mental Illness Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Mental Illness Drugs by: Type Disorders (Volume)
        • 5.3.4.1. Anxiety disorders
        • 5.3.4.2. Depression, bipolar disorder
        • 5.3.4.3. Eating disorders
        • 5.3.4.4. Personality disorders
        • 5.3.4.5. Post-traumatic stress disorder
        • 5.3.4.6. Others
      • 5.3.5. Global Mental Illness Drugs by: Dosage (Volume)
        • 5.3.5.1. Oral
        • 5.3.5.2. Injectables
      • 5.3.6. Global Mental Illness Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Mental Illness Drugs (Price)
      • 5.4.1. Global Mental Illness Drugs by: Type (Price)
  • 6. Mental Illness Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson and Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alkermes (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Mental Illness Drugs Sale, by Type, Application, Distribution Channel, Type Disorders, Dosage and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Mental Illness Drugs (Value)
      • 7.2.1. Global Mental Illness Drugs by: Type (Value)
        • 7.2.1.1. Antipsychotics
        • 7.2.1.2. Antidepressants
        • 7.2.1.3. Antianxiety (anxiolytics)
        • 7.2.1.4. Anti-seizure medications
      • 7.2.2. Global Mental Illness Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Drugstore
      • 7.2.3. Global Mental Illness Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Mental Illness Drugs by: Type Disorders (Value)
        • 7.2.4.1. Anxiety disorders
        • 7.2.4.2. Depression, bipolar disorder
        • 7.2.4.3. Eating disorders
        • 7.2.4.4. Personality disorders
        • 7.2.4.5. Post-traumatic stress disorder
        • 7.2.4.6. Others
      • 7.2.5. Global Mental Illness Drugs by: Dosage (Value)
        • 7.2.5.1. Oral
        • 7.2.5.2. Injectables
      • 7.2.6. Global Mental Illness Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Mental Illness Drugs (Volume)
      • 7.3.1. Global Mental Illness Drugs by: Type (Volume)
        • 7.3.1.1. Antipsychotics
        • 7.3.1.2. Antidepressants
        • 7.3.1.3. Antianxiety (anxiolytics)
        • 7.3.1.4. Anti-seizure medications
      • 7.3.2. Global Mental Illness Drugs by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Drugstore
      • 7.3.3. Global Mental Illness Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Mental Illness Drugs by: Type Disorders (Volume)
        • 7.3.4.1. Anxiety disorders
        • 7.3.4.2. Depression, bipolar disorder
        • 7.3.4.3. Eating disorders
        • 7.3.4.4. Personality disorders
        • 7.3.4.5. Post-traumatic stress disorder
        • 7.3.4.6. Others
      • 7.3.5. Global Mental Illness Drugs by: Dosage (Volume)
        • 7.3.5.1. Oral
        • 7.3.5.2. Injectables
      • 7.3.6. Global Mental Illness Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Mental Illness Drugs (Price)
      • 7.4.1. Global Mental Illness Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mental Illness Drugs: by Type(USD Million)
  • Table 2. Mental Illness Drugs Antipsychotics , by Region USD Million (2017-2022)
  • Table 3. Mental Illness Drugs Antidepressants , by Region USD Million (2017-2022)
  • Table 4. Mental Illness Drugs Antianxiety (anxiolytics) , by Region USD Million (2017-2022)
  • Table 5. Mental Illness Drugs Anti-seizure medications , by Region USD Million (2017-2022)
  • Table 6. Mental Illness Drugs: by Application(USD Million)
  • Table 7. Mental Illness Drugs Hospital , by Region USD Million (2017-2022)
  • Table 8. Mental Illness Drugs Clinic , by Region USD Million (2017-2022)
  • Table 9. Mental Illness Drugs Drugstore , by Region USD Million (2017-2022)
  • Table 10. Mental Illness Drugs: by Distribution Channel(USD Million)
  • Table 11. Mental Illness Drugs Online , by Region USD Million (2017-2022)
  • Table 12. Mental Illness Drugs Offline , by Region USD Million (2017-2022)
  • Table 13. Mental Illness Drugs: by Type Disorders(USD Million)
  • Table 14. Mental Illness Drugs Anxiety disorders , by Region USD Million (2017-2022)
  • Table 15. Mental Illness Drugs Depression, bipolar disorder , by Region USD Million (2017-2022)
  • Table 16. Mental Illness Drugs Eating disorders , by Region USD Million (2017-2022)
  • Table 17. Mental Illness Drugs Personality disorders , by Region USD Million (2017-2022)
  • Table 18. Mental Illness Drugs Post-traumatic stress disorder , by Region USD Million (2017-2022)
  • Table 19. Mental Illness Drugs Others , by Region USD Million (2017-2022)
  • Table 20. Mental Illness Drugs: by Dosage(USD Million)
  • Table 21. Mental Illness Drugs Oral , by Region USD Million (2017-2022)
  • Table 22. Mental Illness Drugs Injectables , by Region USD Million (2017-2022)
  • Table 23. South America Mental Illness Drugs, by Country USD Million (2017-2022)
  • Table 24. South America Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 25. South America Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 26. South America Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 27. South America Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 28. South America Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 29. Brazil Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 30. Brazil Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 31. Brazil Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 32. Brazil Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 33. Brazil Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 34. Argentina Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 35. Argentina Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 36. Argentina Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 37. Argentina Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 38. Argentina Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 39. Rest of South America Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 40. Rest of South America Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 41. Rest of South America Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 42. Rest of South America Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 43. Rest of South America Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 44. Asia Pacific Mental Illness Drugs, by Country USD Million (2017-2022)
  • Table 45. Asia Pacific Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 46. Asia Pacific Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 47. Asia Pacific Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 48. Asia Pacific Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 49. Asia Pacific Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 50. China Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 51. China Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 52. China Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 53. China Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 54. China Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 55. Japan Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 56. Japan Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 57. Japan Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 58. Japan Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 59. Japan Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 60. India Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 61. India Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 62. India Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 63. India Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 64. India Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 65. South Korea Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 66. South Korea Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 67. South Korea Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 68. South Korea Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 69. South Korea Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 70. Taiwan Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 71. Taiwan Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 72. Taiwan Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 73. Taiwan Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 74. Taiwan Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 75. Australia Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 76. Australia Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 77. Australia Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 78. Australia Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 79. Australia Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 85. Europe Mental Illness Drugs, by Country USD Million (2017-2022)
  • Table 86. Europe Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 87. Europe Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 88. Europe Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 89. Europe Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 90. Europe Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 91. Germany Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 92. Germany Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 93. Germany Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 94. Germany Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 95. Germany Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 96. France Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 97. France Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 98. France Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 99. France Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 100. France Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 101. Italy Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 102. Italy Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 103. Italy Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 104. Italy Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 105. Italy Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 106. United Kingdom Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 107. United Kingdom Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 108. United Kingdom Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 109. United Kingdom Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 110. United Kingdom Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 111. Netherlands Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 112. Netherlands Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 113. Netherlands Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 114. Netherlands Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 115. Netherlands Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 116. Rest of Europe Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 117. Rest of Europe Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 118. Rest of Europe Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 119. Rest of Europe Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 120. Rest of Europe Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 121. MEA Mental Illness Drugs, by Country USD Million (2017-2022)
  • Table 122. MEA Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 123. MEA Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 124. MEA Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 125. MEA Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 126. MEA Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 127. Middle East Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 128. Middle East Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 129. Middle East Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 130. Middle East Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 131. Middle East Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 132. Africa Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 133. Africa Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 134. Africa Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 135. Africa Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 136. Africa Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 137. North America Mental Illness Drugs, by Country USD Million (2017-2022)
  • Table 138. North America Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 139. North America Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 140. North America Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 141. North America Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 142. North America Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 143. United States Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 144. United States Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 145. United States Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 146. United States Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 147. United States Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 148. Canada Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 149. Canada Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 150. Canada Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 151. Canada Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 152. Canada Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 153. Mexico Mental Illness Drugs, by Type USD Million (2017-2022)
  • Table 154. Mexico Mental Illness Drugs, by Application USD Million (2017-2022)
  • Table 155. Mexico Mental Illness Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 156. Mexico Mental Illness Drugs, by Type Disorders USD Million (2017-2022)
  • Table 157. Mexico Mental Illness Drugs, by Dosage USD Million (2017-2022)
  • Table 158. Mental Illness Drugs Sales: by Type(K Tons)
  • Table 159. Mental Illness Drugs Sales Antipsychotics , by Region K Tons (2017-2022)
  • Table 160. Mental Illness Drugs Sales Antidepressants , by Region K Tons (2017-2022)
  • Table 161. Mental Illness Drugs Sales Antianxiety (anxiolytics) , by Region K Tons (2017-2022)
  • Table 162. Mental Illness Drugs Sales Anti-seizure medications , by Region K Tons (2017-2022)
  • Table 163. Mental Illness Drugs Sales: by Application(K Tons)
  • Table 164. Mental Illness Drugs Sales Hospital , by Region K Tons (2017-2022)
  • Table 165. Mental Illness Drugs Sales Clinic , by Region K Tons (2017-2022)
  • Table 166. Mental Illness Drugs Sales Drugstore , by Region K Tons (2017-2022)
  • Table 167. Mental Illness Drugs Sales: by Distribution Channel(K Tons)
  • Table 168. Mental Illness Drugs Sales Online , by Region K Tons (2017-2022)
  • Table 169. Mental Illness Drugs Sales Offline , by Region K Tons (2017-2022)
  • Table 170. Mental Illness Drugs Sales: by Type Disorders(K Tons)
  • Table 171. Mental Illness Drugs Sales Anxiety disorders , by Region K Tons (2017-2022)
  • Table 172. Mental Illness Drugs Sales Depression, bipolar disorder , by Region K Tons (2017-2022)
  • Table 173. Mental Illness Drugs Sales Eating disorders , by Region K Tons (2017-2022)
  • Table 174. Mental Illness Drugs Sales Personality disorders , by Region K Tons (2017-2022)
  • Table 175. Mental Illness Drugs Sales Post-traumatic stress disorder , by Region K Tons (2017-2022)
  • Table 176. Mental Illness Drugs Sales Others , by Region K Tons (2017-2022)
  • Table 177. Mental Illness Drugs Sales: by Dosage(K Tons)
  • Table 178. Mental Illness Drugs Sales Oral , by Region K Tons (2017-2022)
  • Table 179. Mental Illness Drugs Sales Injectables , by Region K Tons (2017-2022)
  • Table 180. South America Mental Illness Drugs Sales, by Country K Tons (2017-2022)
  • Table 181. South America Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 182. South America Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 183. South America Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 184. South America Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 185. South America Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 186. Brazil Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 187. Brazil Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 188. Brazil Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 189. Brazil Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 190. Brazil Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 191. Argentina Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 192. Argentina Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 193. Argentina Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 194. Argentina Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 195. Argentina Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 196. Rest of South America Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 197. Rest of South America Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 198. Rest of South America Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 199. Rest of South America Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 200. Rest of South America Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 201. Asia Pacific Mental Illness Drugs Sales, by Country K Tons (2017-2022)
  • Table 202. Asia Pacific Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 203. Asia Pacific Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 204. Asia Pacific Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 205. Asia Pacific Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 206. Asia Pacific Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 207. China Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 208. China Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 209. China Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 210. China Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 211. China Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 212. Japan Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 213. Japan Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 214. Japan Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 215. Japan Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 216. Japan Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 217. India Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 218. India Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 219. India Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 220. India Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 221. India Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 222. South Korea Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 223. South Korea Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 224. South Korea Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 225. South Korea Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 226. South Korea Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 227. Taiwan Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 228. Taiwan Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 229. Taiwan Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 230. Taiwan Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 231. Taiwan Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 232. Australia Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 233. Australia Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 234. Australia Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 235. Australia Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 236. Australia Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 237. Rest of Asia-Pacific Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 238. Rest of Asia-Pacific Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 239. Rest of Asia-Pacific Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 240. Rest of Asia-Pacific Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 241. Rest of Asia-Pacific Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 242. Europe Mental Illness Drugs Sales, by Country K Tons (2017-2022)
  • Table 243. Europe Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 244. Europe Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 245. Europe Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 246. Europe Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 247. Europe Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 248. Germany Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 249. Germany Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 250. Germany Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 251. Germany Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 252. Germany Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 253. France Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 254. France Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 255. France Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 256. France Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 257. France Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 258. Italy Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 259. Italy Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 260. Italy Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 261. Italy Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 262. Italy Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 263. United Kingdom Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 264. United Kingdom Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 265. United Kingdom Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 266. United Kingdom Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 267. United Kingdom Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 268. Netherlands Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 269. Netherlands Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 270. Netherlands Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 271. Netherlands Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 272. Netherlands Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 273. Rest of Europe Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 274. Rest of Europe Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 275. Rest of Europe Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 276. Rest of Europe Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 277. Rest of Europe Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 278. MEA Mental Illness Drugs Sales, by Country K Tons (2017-2022)
  • Table 279. MEA Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 280. MEA Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 281. MEA Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 282. MEA Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 283. MEA Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 284. Middle East Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 285. Middle East Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 286. Middle East Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 287. Middle East Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 288. Middle East Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 289. Africa Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 290. Africa Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 291. Africa Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 292. Africa Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 293. Africa Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 294. North America Mental Illness Drugs Sales, by Country K Tons (2017-2022)
  • Table 295. North America Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 296. North America Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 297. North America Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 298. North America Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 299. North America Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 300. United States Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 301. United States Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 302. United States Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 303. United States Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 304. United States Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 305. Canada Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 306. Canada Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 307. Canada Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 308. Canada Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 309. Canada Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 310. Mexico Mental Illness Drugs Sales, by Type K Tons (2017-2022)
  • Table 311. Mexico Mental Illness Drugs Sales, by Application K Tons (2017-2022)
  • Table 312. Mexico Mental Illness Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 313. Mexico Mental Illness Drugs Sales, by Type Disorders K Tons (2017-2022)
  • Table 314. Mexico Mental Illness Drugs Sales, by Dosage K Tons (2017-2022)
  • Table 315. Mental Illness Drugs: by Type(USD/Units)
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Mental Illness Drugs: by Type(USD Million)
  • Table 325. Mental Illness Drugs Antipsychotics , by Region USD Million (2023-2028)
  • Table 326. Mental Illness Drugs Antidepressants , by Region USD Million (2023-2028)
  • Table 327. Mental Illness Drugs Antianxiety (anxiolytics) , by Region USD Million (2023-2028)
  • Table 328. Mental Illness Drugs Anti-seizure medications , by Region USD Million (2023-2028)
  • Table 329. Mental Illness Drugs: by Application(USD Million)
  • Table 330. Mental Illness Drugs Hospital , by Region USD Million (2023-2028)
  • Table 331. Mental Illness Drugs Clinic , by Region USD Million (2023-2028)
  • Table 332. Mental Illness Drugs Drugstore , by Region USD Million (2023-2028)
  • Table 333. Mental Illness Drugs: by Distribution Channel(USD Million)
  • Table 334. Mental Illness Drugs Online , by Region USD Million (2023-2028)
  • Table 335. Mental Illness Drugs Offline , by Region USD Million (2023-2028)
  • Table 336. Mental Illness Drugs: by Type Disorders(USD Million)
  • Table 337. Mental Illness Drugs Anxiety disorders , by Region USD Million (2023-2028)
  • Table 338. Mental Illness Drugs Depression, bipolar disorder , by Region USD Million (2023-2028)
  • Table 339. Mental Illness Drugs Eating disorders , by Region USD Million (2023-2028)
  • Table 340. Mental Illness Drugs Personality disorders , by Region USD Million (2023-2028)
  • Table 341. Mental Illness Drugs Post-traumatic stress disorder , by Region USD Million (2023-2028)
  • Table 342. Mental Illness Drugs Others , by Region USD Million (2023-2028)
  • Table 343. Mental Illness Drugs: by Dosage(USD Million)
  • Table 344. Mental Illness Drugs Oral , by Region USD Million (2023-2028)
  • Table 345. Mental Illness Drugs Injectables , by Region USD Million (2023-2028)
  • Table 346. South America Mental Illness Drugs, by Country USD Million (2023-2028)
  • Table 347. South America Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 348. South America Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 349. South America Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 350. South America Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 351. South America Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 352. Brazil Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 353. Brazil Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 354. Brazil Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 355. Brazil Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 356. Brazil Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 357. Argentina Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 358. Argentina Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 359. Argentina Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 360. Argentina Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 361. Argentina Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 362. Rest of South America Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 363. Rest of South America Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 364. Rest of South America Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 365. Rest of South America Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 366. Rest of South America Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 367. Asia Pacific Mental Illness Drugs, by Country USD Million (2023-2028)
  • Table 368. Asia Pacific Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 369. Asia Pacific Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 370. Asia Pacific Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 371. Asia Pacific Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 372. Asia Pacific Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 373. China Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 374. China Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 375. China Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 376. China Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 377. China Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 378. Japan Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 379. Japan Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 380. Japan Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 381. Japan Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 382. Japan Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 383. India Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 384. India Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 385. India Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 386. India Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 387. India Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 388. South Korea Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 389. South Korea Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 390. South Korea Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 391. South Korea Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 392. South Korea Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 393. Taiwan Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 394. Taiwan Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 395. Taiwan Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 396. Taiwan Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 397. Taiwan Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 398. Australia Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 399. Australia Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 400. Australia Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 401. Australia Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 402. Australia Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 403. Rest of Asia-Pacific Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 404. Rest of Asia-Pacific Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 405. Rest of Asia-Pacific Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 406. Rest of Asia-Pacific Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 407. Rest of Asia-Pacific Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 408. Europe Mental Illness Drugs, by Country USD Million (2023-2028)
  • Table 409. Europe Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 410. Europe Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 411. Europe Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 412. Europe Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 413. Europe Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 414. Germany Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 415. Germany Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 416. Germany Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 417. Germany Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 418. Germany Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 419. France Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 420. France Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 421. France Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 422. France Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 423. France Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 424. Italy Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 425. Italy Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 426. Italy Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 427. Italy Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 428. Italy Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 429. United Kingdom Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 430. United Kingdom Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 431. United Kingdom Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 432. United Kingdom Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 433. United Kingdom Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 434. Netherlands Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 435. Netherlands Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 436. Netherlands Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 437. Netherlands Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 438. Netherlands Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 439. Rest of Europe Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 440. Rest of Europe Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 441. Rest of Europe Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 442. Rest of Europe Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 443. Rest of Europe Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 444. MEA Mental Illness Drugs, by Country USD Million (2023-2028)
  • Table 445. MEA Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 446. MEA Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 447. MEA Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 448. MEA Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 449. MEA Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 450. Middle East Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 451. Middle East Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 452. Middle East Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 453. Middle East Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 454. Middle East Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 455. Africa Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 456. Africa Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 457. Africa Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 458. Africa Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 459. Africa Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 460. North America Mental Illness Drugs, by Country USD Million (2023-2028)
  • Table 461. North America Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 462. North America Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 463. North America Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 464. North America Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 465. North America Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 466. United States Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 467. United States Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 468. United States Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 469. United States Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 470. United States Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 471. Canada Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 472. Canada Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 473. Canada Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 474. Canada Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 475. Canada Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 476. Mexico Mental Illness Drugs, by Type USD Million (2023-2028)
  • Table 477. Mexico Mental Illness Drugs, by Application USD Million (2023-2028)
  • Table 478. Mexico Mental Illness Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 479. Mexico Mental Illness Drugs, by Type Disorders USD Million (2023-2028)
  • Table 480. Mexico Mental Illness Drugs, by Dosage USD Million (2023-2028)
  • Table 481. Mental Illness Drugs Sales: by Type(K Tons)
  • Table 482. Mental Illness Drugs Sales Antipsychotics , by Region K Tons (2023-2028)
  • Table 483. Mental Illness Drugs Sales Antidepressants , by Region K Tons (2023-2028)
  • Table 484. Mental Illness Drugs Sales Antianxiety (anxiolytics) , by Region K Tons (2023-2028)
  • Table 485. Mental Illness Drugs Sales Anti-seizure medications , by Region K Tons (2023-2028)
  • Table 486. Mental Illness Drugs Sales: by Application(K Tons)
  • Table 487. Mental Illness Drugs Sales Hospital , by Region K Tons (2023-2028)
  • Table 488. Mental Illness Drugs Sales Clinic , by Region K Tons (2023-2028)
  • Table 489. Mental Illness Drugs Sales Drugstore , by Region K Tons (2023-2028)
  • Table 490. Mental Illness Drugs Sales: by Distribution Channel(K Tons)
  • Table 491. Mental Illness Drugs Sales Online , by Region K Tons (2023-2028)
  • Table 492. Mental Illness Drugs Sales Offline , by Region K Tons (2023-2028)
  • Table 493. Mental Illness Drugs Sales: by Type Disorders(K Tons)
  • Table 494. Mental Illness Drugs Sales Anxiety disorders , by Region K Tons (2023-2028)
  • Table 495. Mental Illness Drugs Sales Depression, bipolar disorder , by Region K Tons (2023-2028)
  • Table 496. Mental Illness Drugs Sales Eating disorders , by Region K Tons (2023-2028)
  • Table 497. Mental Illness Drugs Sales Personality disorders , by Region K Tons (2023-2028)
  • Table 498. Mental Illness Drugs Sales Post-traumatic stress disorder , by Region K Tons (2023-2028)
  • Table 499. Mental Illness Drugs Sales Others , by Region K Tons (2023-2028)
  • Table 500. Mental Illness Drugs Sales: by Dosage(K Tons)
  • Table 501. Mental Illness Drugs Sales Oral , by Region K Tons (2023-2028)
  • Table 502. Mental Illness Drugs Sales Injectables , by Region K Tons (2023-2028)
  • Table 503. South America Mental Illness Drugs Sales, by Country K Tons (2023-2028)
  • Table 504. South America Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 505. South America Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 506. South America Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 507. South America Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 508. South America Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 509. Brazil Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 510. Brazil Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 511. Brazil Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 512. Brazil Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 513. Brazil Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 514. Argentina Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 515. Argentina Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 516. Argentina Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 517. Argentina Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 518. Argentina Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 519. Rest of South America Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 520. Rest of South America Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 521. Rest of South America Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 522. Rest of South America Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 523. Rest of South America Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 524. Asia Pacific Mental Illness Drugs Sales, by Country K Tons (2023-2028)
  • Table 525. Asia Pacific Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 526. Asia Pacific Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 527. Asia Pacific Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 528. Asia Pacific Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 529. Asia Pacific Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 530. China Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 531. China Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 532. China Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 533. China Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 534. China Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 535. Japan Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 536. Japan Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 537. Japan Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 538. Japan Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 539. Japan Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 540. India Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 541. India Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 542. India Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 543. India Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 544. India Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 545. South Korea Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 546. South Korea Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 547. South Korea Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 548. South Korea Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 549. South Korea Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 550. Taiwan Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 551. Taiwan Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 552. Taiwan Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 553. Taiwan Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 554. Taiwan Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 555. Australia Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 556. Australia Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 557. Australia Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 558. Australia Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 559. Australia Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 560. Rest of Asia-Pacific Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 561. Rest of Asia-Pacific Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 562. Rest of Asia-Pacific Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 563. Rest of Asia-Pacific Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 564. Rest of Asia-Pacific Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 565. Europe Mental Illness Drugs Sales, by Country K Tons (2023-2028)
  • Table 566. Europe Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 567. Europe Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 568. Europe Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 569. Europe Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 570. Europe Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 571. Germany Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 572. Germany Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 573. Germany Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 574. Germany Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 575. Germany Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 576. France Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 577. France Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 578. France Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 579. France Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 580. France Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 581. Italy Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 582. Italy Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 583. Italy Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 584. Italy Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 585. Italy Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 586. United Kingdom Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 587. United Kingdom Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 588. United Kingdom Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 589. United Kingdom Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 590. United Kingdom Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 591. Netherlands Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 592. Netherlands Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 593. Netherlands Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 594. Netherlands Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 595. Netherlands Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 596. Rest of Europe Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 597. Rest of Europe Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 598. Rest of Europe Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 599. Rest of Europe Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 600. Rest of Europe Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 601. MEA Mental Illness Drugs Sales, by Country K Tons (2023-2028)
  • Table 602. MEA Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 603. MEA Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 604. MEA Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 605. MEA Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 606. MEA Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 607. Middle East Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 608. Middle East Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 609. Middle East Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 610. Middle East Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 611. Middle East Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 612. Africa Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 613. Africa Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 614. Africa Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 615. Africa Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 616. Africa Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 617. North America Mental Illness Drugs Sales, by Country K Tons (2023-2028)
  • Table 618. North America Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 619. North America Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 620. North America Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 621. North America Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 622. North America Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 623. United States Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 624. United States Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 625. United States Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 626. United States Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 627. United States Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 628. Canada Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 629. Canada Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 630. Canada Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 631. Canada Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 632. Canada Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 633. Mexico Mental Illness Drugs Sales, by Type K Tons (2023-2028)
  • Table 634. Mexico Mental Illness Drugs Sales, by Application K Tons (2023-2028)
  • Table 635. Mexico Mental Illness Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 636. Mexico Mental Illness Drugs Sales, by Type Disorders K Tons (2023-2028)
  • Table 637. Mexico Mental Illness Drugs Sales, by Dosage K Tons (2023-2028)
  • Table 638. Mental Illness Drugs: by Type(USD/Units)
  • Table 639. Research Programs/Design for This Report
  • Table 640. Key Data Information from Secondary Sources
  • Table 641. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mental Illness Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Mental Illness Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Mental Illness Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Mental Illness Drugs: by Type Disorders USD Million (2017-2022)
  • Figure 8. Global Mental Illness Drugs: by Dosage USD Million (2017-2022)
  • Figure 9. South America Mental Illness Drugs Share (%), by Country
  • Figure 10. Asia Pacific Mental Illness Drugs Share (%), by Country
  • Figure 11. Europe Mental Illness Drugs Share (%), by Country
  • Figure 12. MEA Mental Illness Drugs Share (%), by Country
  • Figure 13. North America Mental Illness Drugs Share (%), by Country
  • Figure 14. Global Mental Illness Drugs: by Type K Tons (2017-2022)
  • Figure 15. Global Mental Illness Drugs: by Application K Tons (2017-2022)
  • Figure 16. Global Mental Illness Drugs: by Distribution Channel K Tons (2017-2022)
  • Figure 17. Global Mental Illness Drugs: by Type Disorders K Tons (2017-2022)
  • Figure 18. Global Mental Illness Drugs: by Dosage K Tons (2017-2022)
  • Figure 19. South America Mental Illness Drugs Share (%), by Country
  • Figure 20. Asia Pacific Mental Illness Drugs Share (%), by Country
  • Figure 21. Europe Mental Illness Drugs Share (%), by Country
  • Figure 22. MEA Mental Illness Drugs Share (%), by Country
  • Figure 23. North America Mental Illness Drugs Share (%), by Country
  • Figure 24. Global Mental Illness Drugs: by Type USD/Units (2017-2022)
  • Figure 25. Global Mental Illness Drugs share by Players 2022 (%)
  • Figure 26. Global Mental Illness Drugs share by Players (Top 3) 2022(%)
  • Figure 27. Global Mental Illness Drugs share by Players (Top 5) 2022(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson and Johnson (United States) Revenue: by Geography 2022
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2022
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 35. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 37. AstraZeneca(United States) Revenue, Net Income and Gross profit
  • Figure 38. AstraZeneca(United States) Revenue: by Geography 2022
  • Figure 39. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 41. Alkermes (Ireland) Revenue, Net Income and Gross profit
  • Figure 42. Alkermes (Ireland) Revenue: by Geography 2022
  • Figure 43. Allergan (United States) Revenue, Net Income and Gross profit
  • Figure 44. Allergan (United States) Revenue: by Geography 2022
  • Figure 45. Global Mental Illness Drugs: by Type USD Million (2023-2028)
  • Figure 46. Global Mental Illness Drugs: by Application USD Million (2023-2028)
  • Figure 47. Global Mental Illness Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 48. Global Mental Illness Drugs: by Type Disorders USD Million (2023-2028)
  • Figure 49. Global Mental Illness Drugs: by Dosage USD Million (2023-2028)
  • Figure 50. South America Mental Illness Drugs Share (%), by Country
  • Figure 51. Asia Pacific Mental Illness Drugs Share (%), by Country
  • Figure 52. Europe Mental Illness Drugs Share (%), by Country
  • Figure 53. MEA Mental Illness Drugs Share (%), by Country
  • Figure 54. North America Mental Illness Drugs Share (%), by Country
  • Figure 55. Global Mental Illness Drugs: by Type K Tons (2023-2028)
  • Figure 56. Global Mental Illness Drugs: by Application K Tons (2023-2028)
  • Figure 57. Global Mental Illness Drugs: by Distribution Channel K Tons (2023-2028)
  • Figure 58. Global Mental Illness Drugs: by Type Disorders K Tons (2023-2028)
  • Figure 59. Global Mental Illness Drugs: by Dosage K Tons (2023-2028)
  • Figure 60. South America Mental Illness Drugs Share (%), by Country
  • Figure 61. Asia Pacific Mental Illness Drugs Share (%), by Country
  • Figure 62. Europe Mental Illness Drugs Share (%), by Country
  • Figure 63. MEA Mental Illness Drugs Share (%), by Country
  • Figure 64. North America Mental Illness Drugs Share (%), by Country
  • Figure 65. Global Mental Illness Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Johnson and Johnson (United States)
  • Pfizer (United States)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline (United Kingdom)
  • AstraZeneca(United States)
  • Bristol-Myers Squibb (United States)
  • Alkermes (Ireland)
  • Allergan (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 209 Pages 52 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mental Illness Drugs Market Quantitative research analysis
Global Mental Illness Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"The increase in the number of patients taking treatment " is seen as one of major growth factors of Mental Illness Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Mental Illness Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Mental Illness Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Fish Vaccine Comprehensive Study by Type (Live, Inactivated, Subunit, DNA, Others), Application (Body in learning how to protect it from viruses), Administration (Oral, Immersion, Injected), Fish (Sa...
$ 3500
Antihistamine Drugs Comprehensive Study by Type (Sedating (Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others), Non-Sedating Antihistamines (Azelastine, Cetiriz...
$ 3750
Dermatophytosis Drugs Comprehensive Study by Application (Superficial Antifungal Infections, Systemic Antifungal Infections), Route of Administration (Oral, Topical, Parenteral), Form (Powder, Ointme...
$ 3350
Pharmaceutical and Medicinal Herbal Extracts Comprehensive Study by Type (Capsule, Tablet, Powder, Others), Application (Treatment, Massage, Medicines), End-Use (Traditional Chinese Medicine, Western...
$ 3350
Clopidogrel Bisulfate Comprehensive Study by Application (Heart Attacks, Strokes, Peripheral Arterial Diseases), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Ret...
$ 3350
Gemcitabine Comprehensive Study by Application (Pancreas Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Soft-Tissue Sarcoma, Metastatic Breast Cancer, Ovarian Cancer), Distribution Channel (Hosp...
$ 3450